Wade T. Iams, M.D.

Instructor

wade.iams@vanderbilt.edu
Faculty Appointments
Instructor in Medicine
Education
M.D., University of Michigan, Ann Arbor, MichiganB.S., Biological Sciences, University of Notre Dame, South Bend, Indiana
Office Address
2220 Pierce Ave
780 Preston Research Building
Nashville, TN 37232
Research Description
Dr. Iams’ primary research interest is identifying innovative applications of blood biomarker analysis in patients with lung cancer. He has helped develop infrastructure to perform key validation research on new technologies for blood biomarker analysis, both during his residency training at Vanderbilt University and his fellowship training at Northwestern University. Results from the early components of this work have been published (most recently in the Journal of Thoracic Oncology, PMID 28951314) and presented at multiple national meetings. As a junior faculty member, he looks forward to continuing this work and keeping Vanderbilt at the leading edge of the field of blood biomarker development. He is also interested in medical education and has served as a Chief Resident during his internal medicine training at Vanderbilt and Chief Fellow during his fellowship training at Northwestern University. He plans to continue to engage in medical education activities and advance the medical education mission of Vanderbilt University Medical Center.
Research Keywords
Liquid biopsy; small cell lung cancer; cell free DNA; circulating tumor cells
Clinical Research Keywords
Medical Oncology; Lung Cancer
Publications
Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer [print-electronic]. 2018 Aug 8/22/2018; PMID: 30197261, PII: S1525-7304(18)30205-5, DOI: 10.1016/j.cllc.2018.08.011, ISSN: 1938-0690.

Iams WT, Lovly CM. Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived. Cancer Discov. 2018 Jul; 8(7): 797-9. PMID: 29967074, PII: 8/7/797, DOI: 10.1158/2159-8290.CD-18-0489, ISSN: 2159-8290.

Galvez C, Abutaleb A, Iams WT, Lindholm PF, Kwaan HC. Fatal massive hemolysis caused by immunoglobulin M anti-c antibody in a patient with newly diagnosed B-cell acute lymphoblastic leukemia: a case report. Clin Case Rep. 2018 Jun; 6(6): 1090-3. PMID: 29881571, PMCID: PMC5986000, PII: CCR31534, DOI: 10.1002/ccr3.1534, ISSN: 2050-0904.

Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018 May 5/16/2018; 6(1): 39. PMID: 29769148, PMCID: PMC5956851, PII: 10.1186/s40425-018-0349-3, DOI: 10.1186/s40425-018-0349-3, ISSN: 2051-1426.

Chae YK, Arya A, Iams W, Cruz M, Mohindra N, Villaflor V, Giles FJ. Immune checkpoint pathways in non-small cell lung cancer. Ann Transl Med. 2018 Mar; 6(5): 88. PMID: 29666811, PMCID: PMC5890048, PII: atm-06-05-88, DOI: 10.21037/atm.2017.09.30, ISSN: 2305-5839.

Chae YK, Chang S, Ko T, Anker J, Agte S, Iams W, Choi WM, Lee K, Cruz M. Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Sci Rep. 2018 Feb 2/13/2018; 8(1): 2918. PMID: 29440769, PMCID: PMC5811447, PII: 10.1038/s41598-018-21061-1, DOI: 10.1038/s41598-018-21061-1, ISSN: 2045-2322.

Chae YK, Galvez C, Anker JF, Iams WT, Bhave M. Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. Cancer Treat. Rev [print-electronic]. 2018 Feb; 63: 116-21. PMID: 29276997, PII: S0305-7372(17)30206-2, DOI: 10.1016/j.ctrv.2017.12.004, ISSN: 1532-1967.

Chae YK, Choi WM, Bae WH, Anker J, Davis AA, Agte S, Iams WT, Cruz M, Matsangou M, Giles FJ. Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer. Sci Rep. 2018 Jan 1/18/2018; 8(1): 1023. PMID: 29348685, PMCID: PMC5773521, PII: 10.1038/s41598-018-19454-3, DOI: 10.1038/s41598-018-19454-3, ISSN: 2045-2322.

Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, Shyr Y, Lim LP, Raymond CK, Lovly CM. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol [print-electronic]. 2018 Jan; 13(1): 112-23. PMID: 28951314, PMCID: PMC5827950, PII: S1556-0864(17)32705-3, DOI: 10.1016/j.jtho.2017.09.1951, ISSN: 1556-1380.

Iams WT, Villaflor VM. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg. 2017 Jul; 41(7): 1719-25. PMID: 28271259, PII: 10.1007/s00268-017-3959-x, DOI: 10.1007/s00268-017-3959-x, ISSN: 1432-2323.

Iams WT, Sosman JA, Chandra S. Novel Targeted Therapies for Metastatic Melanoma. Cancer J. 2016 Dec; 23(1): 54-8. PMID: 28114255, PII: 00130404-201701000-00008, DOI: 10.1097/PPO.0000000000000242, ISSN: 1540-336X.

Bregman J, Iams W, Theobald C. Urethral Trauma After Foley Catheter Placement: A Teachable Moment. JAMA Intern Med. 2016 Nov 11/1/2016; 176(11): 1606-7. PMID: 27654098, PII: 2553297, DOI: 10.1001/jamainternmed.2016.5438, ISSN: 2168-6114.

Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA. Major milestones in translational oncology. BMC Med. 2016 Jul 7/28/2016; 14(1): 110. PMID: 27469586, PMCID: PMC4964079, PII: 10.1186/s12916-016-0654-y, DOI: 10.1186/s12916-016-0654-y, ISSN: 1741-7015.

Iams W, Heck J, Kapp M, Leverenz D, Vella M, Szentirmai E, Valerio-Navarrete I, Theobald C, Goggins K, Flemmons K, Sponsler K, Penrod C, Kleinholz P, Brady D, Kripalani S. A Multidisciplinary Housestaff-Led Initiative to Safely Reduce Daily Laboratory Testing. Acad Med. 2016 Jun; 91(6): 813-20. PMID: 27028031, DOI: 10.1097/ACM.0000000000001149, ISSN: 1938-808X.

Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer¿. Lung Cancer [print-electronic]. 2016 Feb; 92: 29-34. PMID: 26775593, PMCID: PMC4874190, PII: S0169-5002(15)30100-8, DOI: 10.1016/j.lungcan.2015.11.004, ISSN: 1872-8332.

Iams WT, Lovly CM. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Clin. Cancer Res. 2015 Oct 10/1/2015; 21(19): 4270-7. PMID: 26429980, PMCID: PMC4593065, PII: 21/19/4270, DOI: 10.1158/1078-0432.CCR-14-2518, ISSN: 1078-0432.

Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep; 21(5): 378-82. PMID: 26389762, PMCID: PMC5242382, PII: 00130404-201509000-00005, DOI: 10.1097/PPO.0000000000000142, ISSN: 1540-336X.

Leverenz D, Iams W, Heck J, Brady D. Who is going to make the wise choice?. J Hosp Med [print-electronic]. 2015 Aug; 10(8): 544-6. PMID: 25980783, DOI: 10.1002/jhm.2377, ISSN: 1553-5606.

Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015 Mar; 3(3): 288-95. PMID: 25736262, PMCID: PMC4351797, DOI: 10.1158/2326-6066.CIR-14-0207, ISSN: 2326-6074.

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3): 431-7. PMID: 25415430, PMCID: PMC4479120, PII: S1556-0864(15)31650-6, DOI: 10.1097/JTO.0000000000000432, ISSN: 1556-1380.

Tsai JP, Iams WT, Greer JP, Morgan DS, Li S, Reddy NM. Alternative intensive induction chemotherapeutic regimens in MYC expressing diffuse large B-cell lymphoma [letter]. Leuk. Lymphoma [print-electronic]. 2015 Mar; 56(3): 797-800. PMID: 24884316, DOI: 10.3109/10428194.2014.928937, ISSN: 1029-2403.

Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM. Increased serum tumor necrosis factor a levels in patients with lenalidomide-induced hypothyroidism. Exp. Hematol [print-electronic]. 2015 Feb; 43(2): 74-8. PMID: 25448491, PMCID: PMC5002942, PII: S0301-472X(14)00715-2, DOI: 10.1016/j.exphem.2014.10.009, ISSN: 1873-2399.

Iams W, Reddy NM. Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective. Ther Adv Hematol. 2014 Oct; 5(5): 153-67. PMID: 25324956, PMCID: PMC4199091, PII: 10.1177_2040620714547327, DOI: 10.1177/2040620714547327, ISSN: 2040-6207.

Zopf DA, Iams W, Kim JC, Baker SR, Moyer JS. Full-thickness skin graft overlying a separately harvested auricular cartilage graft for nasal alar reconstruction. JAMA Facial Plast Surg. 2013 Mar 3/1/2013; 15(2): 131-4. PMID: 23519340, PII: 1670933, DOI: 10.1001/2013.jamafacial.25, ISSN: 2168-6092.

Iams W, Beckermann KE, Neff AT, Mayer IA, Abramson VG. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Med. Oncol [print-electronic]. 2013; 30(2): 568. PMID: 23564368, PMCID: PMC3774143, DOI: 10.1007/s12032-013-0568-x, ISSN: 1559-131X.

Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ. Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology [print-electronic]. 2010 Aug; 130(4): 572-88. PMID: 20406305, PMCID: PMC2913268, PII: IMM3261, DOI: 10.1111/j.1365-2567.2010.03261.x, ISSN: 1365-2567.